Product Name :
ABT-333
Description:
Dasabuvir, also known as ABT-333, is a non-nucleoside polymerase inhibitor currently under clinical trials for the treatment of Hepatitis C. In the United States, it is approved by the Food and Drug Administration for use in combination with ombitasvir, paritaprevir, and ritonavir in the product Viekira Pak. Dasabuvir acts as a NS5B (an RNA-directed RNA polymerase) inhibitor.
CAS:
1132935-63-7
Molecular Weight:
493.57
Formula:
C26H27N3O5S
Chemical Name:
N-{6-[3-tert-butyl-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide
Smiles :
COC1C(=CC(=CC=1C(C)(C)C)N1C=CC(=O)NC1=O)C1=CC2=CC=C(C=C2C=C1)NS(C)(=O)=O
InChiKey:
NBRBXGKOEOGLOI-UHFFFAOYSA-N
InChi :
InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Dasabuvir, also known as ABT-333, is a non-nucleoside polymerase inhibitor currently under clinical trials for the treatment of Hepatitis C. In the United States, it is approved by the Food and Drug Administration for use in combination with ombitasvir, paritaprevir, and ritonavir in the product Viekira Pak. Dasabuvir acts as a NS5B (an RNA-directed RNA polymerase) inhibitor.|Product information|CAS Number: 1132935-63-7|Molecular Weight: 493.57|Formula: C26H27N3O5S|Synonym:|Dasabuvir|ABT333|ABT 333|Chemical Name: N-{6-[3-tert-butyl-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide|Smiles: COC1C(=CC(=CC=1C(C)(C)C)N1C=CC(=O)NC1=O)C1=CC2=CC=C(C=C2C=C1)NS(C)(=O)=O|InChiKey: NBRBXGKOEOGLOI-UHFFFAOYSA-N|InChi: InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: Soluble in DMSO|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ABT-333 (Dasabuvir) is at least 7, 000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. ABT-333 (Dasabuvir) inhibits the polymerase enzymatic activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC50s between 2.2 and 10.7 nM. ABT-333 inhibits replication of HCV subgenomic replicons in cell culture assays, with EC50 values of 7.{{OPC 4392} site|{OPC 4392} Dopamine Receptor|{OPC 4392} TGF-beta/Smad|{OPC 4392} Protocol|{OPC 4392} In Vivo|{OPC 4392} supplier} 7 and 1.{{Mecillinam} medchemexpress|{Mecillinam} Antibiotic|{Mecillinam} Epigenetics|{Mecillinam} Protocol|{Mecillinam} References|{Mecillinam} supplier} 8 nM against genotype 1a (H77) and 1b (Con1), respectively.PMID:23756629 In the presence of 40% human plasma, there is a 12- to 13-fold decrease in inhibitory potency, yielding EC50s of 99 and 21 nM for HCV genotype 1a (H77) and 1b (Con1) replicons, respectively.|In Vivo:|The recombinant HCV polymerases used in this study contain the first 570 amino acids of the 591-amino acid native protein sequence, with a six-histidine tag at the N terminus to facilitate purification by affinity chromatography. Briefly, ABT-333 (Dasabuvir) is incubated with 5 to 50 nM polymerase for 15 min at room temperature, follow by the addition of nucleoside triphosphates (NTPs) and [3H]UTP for 3 h at 30°C. After termination of the reaction, the precipitated RNA is captured by filtration through a GF/B filter. The amount of incorporated [3H]UTP is measured by scintillation counting with a Wallac 1450 MicroBeta counter. The percent inhibition is calculated from the initial rates of inhibited reactions relative to that of the uninhibited control reaction. The mean 50% inhibitory concentration (IC50) and the standard error of the mean (SEM) are calculated via nonlinear regression.|References:|Kati W, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11.Products are for research use only. Not for human use.|
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites:
https://www.medchemexpress.com